Cargando…
Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
High-risk subtypes of B-cell acute lymphoblastic leukemia (B-ALL) are frequently associated with aberrant activation of tyrosine kinases (TKs). These include Ph+ B-ALL driven by BCR-ABL, and Ph-like B-ALL that carries other chromosomal rearrangements and/or gene mutations that activate TK signaling....
Autores principales: | Buono, Roberta, Alhaddad, Muneera, Fruman, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140551/ https://www.ncbi.nlm.nih.gov/pubmed/37124486 http://dx.doi.org/10.3389/fonc.2023.1162694 |
Ejemplares similares
-
Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019) -
Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018) -
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014) -
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016) -
Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)